Some people with idiopathic pulmonary fibrosis
may be eligible to participate in an experimental clinical trial at the Warren Grant Magnuson Clinical Center of the National Institutes of Health in Bethesda, Maryland.
Open label Phase II studies in idiopathic pulmonary fibrosis
, AlstrAaAaAe syndrome, and type 2 diabetes have provided preliminary evidence that the results seen in preclinical models translate into the corresponding human diseases.
Efficacy of Nintedanib in Idiopathic Pulmonary Fibrosis
across Prespecified Subgroups in INPULSIS.
A review of the Idiopathic Pulmonary Fibrosis
products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
Additionally, the company has executed a series of agreements aimed at further advancing its fibrosis development program, including an option to acquire Galecto Biotech AB, a company with an inhaled inhibitor of galectin-3 in Phase 1 development for the treatment of idiopathic pulmonary fibrosis
, a research collaboration and license agreement with the California Institute for Biomedical Research (Calibr), and a translational research collaboration with The Medical University of South Carolina.
Incidence of pulmonary hypertension in idiopathic pulmonary fibrosis
Significance of bronchoalveolar lavage for the diagnosis of idiopathic pulmonary fibrosis
Hypothesizing that idiopathic pulmonary fibrosis
may stem from sequential lung injury and subsequent aberrant wound healing without significant inflammation, researchers have turned their attention to drugs that alter fibroproliferative mechanisms, Dr.
The agreement also calls for InterMune to take a non-controlling equity stake in Mondobiotech in exchange for a patent license that covers the use of Interferon gamma-1b for idiopathic pulmonary fibrosis
in certain European countries and for bronchial asthma worldwide.
We also have two active Phase III clinical trials with ACTIMMUNE(R), including a trial for idiopathic pulmonary fibrosis
(IPF) and one for multidrug-resistant tuberculosis (MDR TB).
Promedior's new facility includes state-of-the-art laboratories to support product development and commercialization of the company's novel Pentraxin-2 therapeutics to treat fibrosis, including a number of rare diseases such as idiopathic pulmonary fibrosis
(IPF) and myelofibrosis.